The winner of a 2025 SITC grant examines mechanisms that may help explain why drugs that work for some forms of lymphoma ...

Today, the Innovative Cancer Medicines (ICM) initiative announced the enrollment of the first Nigerian patient in a pioneering demonstration project to provide an immunotherapy drug used to treat ...

CREATE Medicines, Inc., formerly Myeloid Therapeutics, Inc. ("CREATE"), announced today that Amsterdam University Medical Center ("Amsterdam UMC") has dosed the first patient in the SPaCE-MT clinical ...

The investigator-initiated study will evaluate Create's MT-302 plus chemo with or without standard immunotherapy and anti-HER2 therapy in the first-line setting.

Patient education conversations emphasize 3 core elements: equivalent efficacy supported by rigorous pharmacokinetic and ...